Compare NABL & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | ZVRA |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 761.3M | 689.4M |
| IPO Year | 2021 | 2015 |
| Metric | NABL | ZVRA |
|---|---|---|
| Price | $4.14 | $11.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $8.31 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 2.3M | 741.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | ★ $511,430,000.00 | $106,470,000.00 |
| Revenue This Year | $11.04 | $37.27 |
| Revenue Next Year | $8.53 | $53.42 |
| P/E Ratio | ★ N/A | $15.31 |
| Revenue Growth | 9.71 | ★ 350.91 |
| 52 Week Low | $2.92 | $8.01 |
| 52 Week High | $8.74 | $15.04 |
| Indicator | NABL | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 43.43 |
| Support Level | $3.81 | $10.81 |
| Resistance Level | $4.24 | $12.19 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 69.07 | 30.53 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.